A citation-based method for searching scientific literature

Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley, George Wilbanks, Santo Nicosia, Alan Cantor, Rebecca Sutphen. Cancer 2005
Times Cited: 491







List of co-cited articles
636 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
861
6

BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Ikuko Sakamoto, Yosuke Hirotsu, Hiroshi Nakagomi, Hidetaka Ouchi, Atsushi Ikegami, Katsuhiro Teramoto, Kenji Amemiya, Hitoshi Mochizuki, Masao Omata. Cancer 2016
39
15

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
309
6

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
201
6

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
6

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J Boyd, Y Sonoda, M G Federici, F Bogomolniy, E Rhei, D L Maresco, P E Saigo, L A Almadrones, R R Barakat, C L Brown,[...]. JAMA 2000
378
6

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
645
6

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
6

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
333
6

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
757
6


Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Angela George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Gore,[...]. Sci Rep 2016
95
6

High grade serous ovarian carcinomas originate in the fallopian tube.
S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen,[...]. Nat Commun 2017
234
6

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
6

Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
6

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Allison W Kurian, Kevin C Ward, Nadia Howlader, Dennis Deapen, Ann S Hamilton, Angela Mariotto, Daniel Miller, Lynne S Penberthy, Steven J Katz. J Clin Oncol 2019
90
6

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
6

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
Fabiola Medeiros, Michael G Muto, Yonghee Lee, Julia A Elvin, Michael J Callahan, Colleen Feltmate, Judy E Garber, Daniel W Cramer, Christopher P Crum. Am J Surg Pathol 2006
553
5

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
C Bethan Powell, Eric Kenley, Lee-May Chen, Beth Crawford, Jane McLennan, Charles Zaloudek, Miriam Komaromy, Mary Beattie, John Ziegler. J Clin Oncol 2005
249
5

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
338
5


Mutations in BRIP1 confer high risk of ovarian cancer.
Thorunn Rafnar, Daniel F Gudbjartsson, Patrick Sulem, Aslaug Jonasdottir, Asgeir Sigurdsson, Adalbjorg Jonasdottir, Soren Besenbacher, Pär Lundin, Simon N Stacey, Julius Gudmundsson,[...]. Nat Genet 2011
235
5

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Joanne Kotsopoulos, Barry Rosen, Isabel Fan, Joel Moody, John R McLaughlin, Harvey Risch, Taymaa May, Ping Sun, Steven A Narod. Gynecol Oncol 2016
51
9

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
323
5

BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Linda Rolnitzky, Sharon Pelles-Avraham, Ravit Geva, Martin Edward Donach, John Curtin, Akiva Novetsky, Tal Grenader,[...]. Mol Cancer Ther 2011
70
7

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Sunil R Lakhani, Sanjiv Manek, Frederique Penault-Llorca, Adrienne Flanagan, Laurent Arnout, Samantha Merrett, Lesley McGuffog, Dawn Steele, Peter Devilee, Jan G M Klijn,[...]. Clin Cancer Res 2004
181
5

BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.
Myong Cheol Lim, Sokbom Kang, Sang-Soo Seo, Sun-Young Kong, Bo-Yon Lee, Seon-Kyung Lee, Sang-Yoon Park. J Cancer Res Clin Oncol 2009
41
12

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
631
5

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R Rebbeck, Nandita Mitra, Fei Wan, Olga M Sinilnikova, Sue Healey, Lesley McGuffog, Sylvie Mazoyer, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou,[...]. JAMA 2015
235
5

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
5

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Angela George, Stan Kaye, Susana Banerjee. Nat Rev Clin Oncol 2017
85
5

Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.
Sue V Petzel, Rachel Isaksson Vogel, Tracy Bensend, Anna Leininger, Peter A Argenta, Melissa A Geller. J Genet Couns 2013
30
16

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Jaya M Satagopan, Jeff Boyd, Noah D Kauff, Mark Robson, Lauren Scheuer, Steven Narod, Kenneth Offit. Clin Cancer Res 2002
110
5

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
5

BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
L Sarantaus, P Vahteristo, E Bloom, A Tamminen, L Unkila-Kallio, R Butzow, H Nevanlinna. Eur J Hum Genet 2001
43
11

The contribution of BRCA1 and BRCA2 to ovarian cancer.
Susan J Ramus, Simon A Gayther. Mol Oncol 2009
106
5

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Ignace Vergote, Susana Banerjee, Anne-Marie Gerdes, Christi van Asperen, Christian Marth, Fatima Vaz, Isabelle Ray-Coquard, Dominique Stoppa-Lyonnet, Antonio Gonzalez-Martin, Jalid Sehouli,[...]. Eur J Cancer 2016
33
15

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
5

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
5

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Barbara Norquist, Kaitlyn A Wurz, Christopher C Pennil, Rochelle Garcia, Jenny Gross, Wataru Sakai, Beth Y Karlan, Toshiyasu Taniguchi, Elizabeth M Swisher. J Clin Oncol 2011
360
5

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
715
5

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
5

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
5

BRCA mutation in high grade epithelial ovarian cancers.
Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn. Gynecol Oncol Rep 2019
14
35

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
269
5

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed Ashour Ahmed, Dariush Etemadmoghadam, Jillian Temple, Andy G Lynch, Mohamed Riad, Raghwa Sharma, Colin Stewart, Sian Fereday, Carlos Caldas, Anna Defazio,[...]. J Pathol 2010
434
4

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
Ruth Perets, Gregory A Wyant, Katherine W Muto, Jonathan G Bijron, Barish B Poole, Kenneth T Chin, Jin Yun H Chen, Anders W Ohman, Corey D Stepule, Soongu Kwak,[...]. Cancer Cell 2013
311
4


Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Susan M Domchek, Tara M Friebel, Susan L Neuhausen, Theresa Wagner, Gareth Evans, Claudine Isaacs, Judy E Garber, Mary B Daly, Rosalind Eeles, Ellen Matloff,[...]. Lancet Oncol 2006
210
4

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.